Long-term follow-up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia

Pierre Feugier,Thérèse Aurran,Beatrice Mahe,Rémi Letestu,Florence Nguyen-Khac,Bruno Cazin,Olivier Tournilhac,Hervé Maisonneuve,Olivier Casasnovas,Alain Delmer,Véronique Leblond,Bruno Royer,Bernadette Corront,Sylvie Chevret,Roselyne Delepine,Sandrine Vaudaux,Eric Van Den Neste,Marie C. Béné,Florence Cymbalista,Damien Roos-Weil,Stéphane Leprêtre

Long-term follow-up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia

2018

In fit chronic lymphocytic leukemia (CLL) patients without chromosome 17p deletion (del(17p)) or TP53 mutation, six cycles of FCR (fludarabine, cyclophosphamide, rituximab) provides the best progression-free survival (PFS) and overall survival (OS).[1][1],[2][2] In 2007, the French Innovative

Keywords:

Chronic lymphocytic leukemia
Immunology
Rituximab
Alemtuzumab
Medicine
Cyclophosphamide
Fludarabine
overall survival
Oncology
Internal medicine
long term follow up
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations